Gall Bladder Dysmotility: a Risk Factor for Gall Stone Formation in Hypertriglyceridaemia and Reversal on Triglyceride Lowering Therapy by Bezafibrate and Fish Oil

Overview

Journal Gut

Specialty Gastroenterology

Date 2002 Dec 13

PMID 12477770

Citations 18

Authors

I J A M Jonkers

A H M Smelt

M Ledeboer

M E Hollum

I Biemond

F Kuipers

F Stellaard

R Boverhof

A E Meinders

C H B W Lamers

A A M Masclee

Affiliations

Soon will be listed here.

Abstract

Background And Aim: The aim of this study was to unravel the mechanisms responsible for the increased risk of gall stone disease in hypertriglyceridaemia (HTG) and to compare the effects of triglyceride lowering therapy by bezafibrate and fish oil on determinants of cholelithiasis (biliary lipid composition and gall bladder motility) in HTG patients.

Patients And Methods: Gall bladder motility (ultrasonography) was studied postprandially and during infusion of cholecystokinin (CCK). Determinants of cholelithiasis and serum lipids were compared between nine HTG patients and 10 age, sex, and body mass index matched normolipidaemic controls. The effects of bezafibrate and fish oil in HTG patients were studied in a randomised cross over trial.

Results: HTG patients showed 14-fold higher serum triglyceride (TG) levels than controls. Biliary lipid composition, fasting gall bladder volumes, and CCK levels did not differ between HTG patients and controls. Gall bladder emptying was reduced in HTG patients compared with controls during CCK infusion (-22%) as well as in response to a meal (-37%; both p<0.001). Postprandial CCK levels were significantly higher in HTG patients. Both bezafibrate and fish oil reduced serum TG levels (-68% and -51% v baseline, respectively; both p<0.01). Fasting CCK levels were not affected whereas CCK induced gall bladder emptying increased during bezafibrate (+29%; p<0.001) and tended to increase on fish oil therapy (+13%; p=0.07). Postprandial gall bladder motility improved on bezafibrate and fish oil (+47 and +25% v baseline, respectively; both p<0.02) at least partly due to increased gall bladder sensitivity to CCK (both p<0.05 v baseline). Bezafibrate but not fish oil increased the molar ratio of cholesterol to bile acids (+40%; p</=0.05) but no effects on cholesterol saturation index were seen with either treatment.

Conclusions: We suggest that impaired gall bladder motility occurs in HTG patients due to decreased sensitivity to CCK, which may add to the enhanced risk of gall stone disease in HTG patients. Triglyceride lowering therapy by both fish oil and bezafibrate improve gall bladder dysmotility without adversely affecting biliary cholesterol saturation.

Citing Articles

Associations between temporal eating patterns and energy distribution patterns with gallstones: a cross-sectional study based on NHANES 2017-2018.

Zhang H, Xu C, Zhu X, Zhang J, Yin J, Yao N BMC Public Health. 2024; 24(1):2994.

PMID: 39472867 PMC: 11523901. DOI: 10.1186/s12889-024-20512-x.

Dietary fatty acids and gallstone risk: insights from NHANES and Mendelian randomization analysis.

Wang M, Guo J, Sun S Front Nutr. 2024; 11:1454648.

PMID: 39211832 PMC: 11358065. DOI: 10.3389/fnut.2024.1454648.

The Impact of Metabolic Factors and Lipid-Lowering Drugs on Common Bile Duct Stone Recurrence after Endoscopic Sphincterotomy with Following Cholecystectomy.

Wang S, Wu C, Sung K, Tsou Y, Lin C, Lee C J Pers Med. 2023; 13(10).

PMID: 37888101 PMC: 10608674. DOI: 10.3390/jpm13101490.

Evidence-based clinical practice guidelines for cholelithiasis 2021.

Fujita N, Yasuda I, Endo I, Isayama H, Iwashita T, Ueki T J Gastroenterol. 2023; 58(9):801-833.

PMID: 37452855 PMC: 10423145. DOI: 10.1007/s00535-023-02014-6.

Evaluation of gallbladder motility assessed by ultrasonography in dogs with hyperlipidemia.

Villm J, DeMonaco S, Panciera D, Larson M, Bolton T J Vet Intern Med. 2023; 37(3):968-975.

PMID: 37199599 PMC: 10229346. DOI: 10.1111/jvim.16713.

References

Ahlberg J, Angelin B, Einarsson K, Hellstrom K, Leijd B . Prevalence of gallbladder disease in hyperlipoproteinemia. Dig Dis Sci. 1979; 24(6):459-64. DOI: 10.1007/BF01299828. View

Palmer R . Effects of fibric acid derivatives on biliary lipid composition. Am J Med. 1987; 83(5B):37-43. DOI: 10.1016/0002-9343(87)90869-2. View

Behar J, Lee K, Thompson W, Biancani P . Gallbladder contraction in patients with pigment and cholesterol stones. Gastroenterology. 1989; 97(6):1479-84. DOI: 10.1016/0016-5085(89)90392-2. View

Toskes P . Hyperlipidemic pancreatitis. Gastroenterol Clin North Am. 1990; 19(4):783-91. View

Everson G . Gallbladder function in gallstone disease. Gastroenterol Clin North Am. 1991; 20(1):85-110. View

Berr F, Schreiber E, Frick U . Interrelationships of bile acid and phospholipid fatty acid species with cholesterol saturation of duodenal bile in health and gallstone disease. Hepatology. 1992; 16(1):71-81. DOI: 10.1002/hep.1840160114. View

Carey M . Critical tables for calculating the cholesterol saturation of native bile. J Lipid Res. 1978; 19(8):945-55. View

Nestel P . Fish oil and cardiovascular disease: lipids and arterial function. Am J Clin Nutr. 2000; 71(1 Suppl):228S-31S. DOI: 10.1093/ajcn/71.1.228S. View

Bandsma R, Kuipers F, Vonk R, Boverhof R, Sauer P, Nagel G . The contribution of newly synthesized cholesterol to bile salt synthesis in rats quantified by mass isotopomer distribution analysis. Biochim Biophys Acta. 2000; 1483(3):343-51. DOI: 10.1016/s1388-1981(99)00192-4. View

10.

de Man F, van der Laarse A, Smelt A, Jukema J, Blauw G . Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin. Arterioscler Thromb Vasc Biol. 2000; 20(3):744-50. DOI: 10.1161/01.atv.20.3.744. View

11.

Moschetta A, vanBerge-Henegouwen G, Portincasa P, Palasciano G, van Erpecum K . Cholesterol crystallization in model biles: effects of bile salt and phospholipid species composition. J Lipid Res. 2001; 42(8):1273-81. View

12.

Murphy G, Billing B, Baron D . A fluorimetric and enzymatic method for the estimation of serum total bile acids. J Clin Pathol. 1970; 23(7):594-8. PMC: 476843. DOI: 10.1136/jcp.23.7.594. View

13.

. Clofibrate and niacin in coronary heart disease. JAMA. 1975; 231(4):360-81. View

14.

Einarsson K, Hellstrom K, Kallner M . Gallbladder disease in hyperlipoproteinaemia. Lancet. 1975; 1(7905):484-7. DOI: 10.1016/s0140-6736(75)92831-7. View

15.

Cooper J, Geizerova H, Oliver M . Letter: Clofibrate and gallstones. Lancet. 1975; 1(7915):1083. DOI: 10.1016/s0140-6736(75)91845-0. View

16.

Carey M, Small D . The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man. J Clin Invest. 1978; 61(4):998-1026. PMC: 372618. DOI: 10.1172/JCI109025. View

17.

Bateson M, Maclean D, Ross P, Bouchier I . Clofibrate therapy and gallstone induction. Am J Dig Dis. 1978; 23(7):623-8. DOI: 10.1007/BF01072597. View

18.

Gamble W, Vaughan M, Kruth H, Avigan J . Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J Lipid Res. 1978; 19(8):1068-70. View

19.

Jebbink M, Masclee A, van der Kleij F, Schipper J, Rovati L, Jansen J . Effect of loxiglumide and atropine on erythromycin-induced reduction in gallbladder volume in human subjects. Hepatology. 1992; 16(4):937-42. DOI: 10.1002/hep.1840160414. View

20.

Berr F, Holl J, Jungst D, Fischer S, Richter W, Seifferth B . Dietary N-3 polyunsaturated fatty acids decrease biliary cholesterol saturation in gallstone disease. Hepatology. 1992; 16(4):960-7. DOI: 10.1002/hep.1840160418. View